Anti-TNFRSF18/GITR/CD357 Antibody (Korea Natl.Cancer Ctr. patent anti-GITR)
Catalog No.
F1861
Anti-TNFRSF18/GITR/CD357 Antibody (Korea Natl.Cancer Ctr. patent anti-GITR)
Featured Products
Korea Natl.Cancer Ctr. patent anti-GITR is a CHO-expressed humanized antibody targeting TNFRSF18 / GITR / CD357.
Quality Control & DataSheet
- View current batch:
-
Purity > 90% by SDS-PAGE and SEC-HPLC analyses.
- MSDS (Material Safety Data Sheet)
- Datasheet
150 kDa
Dry ice
-80°C
2 years
Liquid
See label
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
Korea Natl.Cancer Ctr. patent anti-GITR
100 mM Pro 20 mM Arg pH 5.0. No preservative!
Q9Y5U5
Human
Unconjugated
Monoclonal
Protein A
IgG1
ELISA, FACS, Kinetics, Functional assay, Animal Model
TNFRSF18 / GITR / CD357
Please avoid freeze-thaw cycles.